These are drugs that generate billions of dollars of revenue for Roche and BI. Our drug would I think fall into a similar pricing bucket. Look, those drugs just reduce the lung function decline. Our drug is preserving and improving lung function. It’s improving symptoms, which of those drugs are not doing and it’s doing so while removing steroid. So I think we’re very confident now that from a pricing standpoint, we would approach some of those similar IPF drugs, which is why a lot of the modeling estimates not only internally, but also with some of you guys have been actually changing. So I do feel better again after our data that it’s generating a bit more confidence that the pricing of the potential pricing of the drug could be much higher than we initially expected.
Hartaj Singh: Yeah. No, that’s great Sanjay. And then the other question can just have is, I was at U.S. and there’s a lot of data presented by larger companies, but I was a little surprised, not in that way, but just how much buzz there was around your presentations, even though I think you had far greater presentations at ATS. What are you thinking in terms of strategic sort of a view? There seemed to be a buzz as aTyr being kind of a small cap company with a product that could play really well to a multinational company that wants to take this product out into many countries all — many geographies all over the world. What are you thinking aside from churn in that regards? Thanks for all the questions.
Sanjay Shukla: Yeah. I think it’s a factor of a couple of things. First, the data needs to get absorbed. I mean, we put it out at ATS. It takes a minute to kind of get worldwide. I think the publication is really going to help us and we’ve already seen even in the couple of days it’s been up. We have new interest from other parts of the world. Pulmonologists are busy. They’re managing a lot of conditions outside of the specialists. This is why I said the generalist will start to pick up on this. The other thing that’s happening is we’re seeing a contraction in the ILD space with a number of companies kind of moving out of the space. They’re finding their therapies are not working as well in preclinical and early phase testing.
You see larger companies moving out of the space. So this is why we feel like aTyr is getting that buzz that you picked up on at Barcelona that our therapy is doing things previously not seen in sarcoidosis with other therapies. And we are the furthest along. Combine that with some competition kind of going away here. We think that can help us certainly enroll. And again, we could come out of this sort of at the top of the wave here in a few years as what I think is a leading ILD company. Last thing I’ll say about ERS and I think you picked up on this, interstitial lung disease is where asthma and COPD was about 15 years ago. At the ERS conference is around 2000, 2005, better new steroid sparing therapies were needed and they came out. LAMA, LABA, some of the anti-muscarinic things like that for asthma and COPD.
Now the shift for respiratory experts is how do we get better drugs in ILD? You’ve seen United do some things with pulmonary hypertension ILD. But right now, we are kind of the leader right now for — we certainly are for sarcoidosis, but our therapy is something that could be really useful in a number of those other conditions. This is why we think it’s a multi-billion dollar opportunity. And we’re hopeful to get noticed more and more in the sort of coming years as we get this data out.
